| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JPS.2600610111 |
| P698 | PubMed publication ID | 5019220 |
| P2093 | author name string | Rowland M | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 70-74 | |
| P577 | publication date | 1972-01-01 | |
| P1433 | published in | Journal of Pharmaceutical Sciences | Q3186933 |
| P1476 | title | Influence of route of administration on drug availability | |
| P478 | volume | 61 |
| Q41974281 | A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs |
| Q53746718 | A further study of the pharmacokinetics of gitoxin in rabbit isolated liver: clearance of 3H-gitoxin. |
| Q41391428 | A nonlinear physiologic pharmacokinetic model: I. Steady-state |
| Q67429765 | A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow |
| Q71564909 | Amitriptyline pharmacokinetics. A crossover study with single doses of amitriptyline and nortriptyline |
| Q92533230 | An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles |
| Q35164876 | Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges |
| Q37706410 | Applications of a recirculatory stochastic pharmacokinetic model: limitations of compartmental models |
| Q41363638 | Birth defects and aplastic anemia: differences in polycyclic hydrocarbon toxicity associated with the Ah locus |
| Q66973905 | Chlorpheniramine. II. Effect of the first-pass metabolism on the oral bioavailability in dogs |
| Q37813042 | Clearance (née Rowland) concepts: a downdate and an update |
| Q34218381 | Clearance concepts in pharmacokinetics |
| Q34184941 | Clinical Pharmacokinetics Pethidine |
| Q34756311 | Clinical pharmacokinetics of mibefradil |
| Q50036214 | Commentary on "The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio". |
| Q72543935 | Comparative pharmacokinetics of benzodiazepines in dog and man |
| Q24542434 | Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects |
| Q70590206 | Comparison of in vivo and ex vivo porcine liver function using the same liver |
| Q89482787 | Critical Analysis of Hepatic Clearance Based on an Advection Mass Transfer Model and Mass Balance |
| Q51850937 | Determinants of drug disposition in patients with cirrhosis. |
| Q39834959 | Development of quantitative structure-pharmacokinetic relationships |
| Q44872539 | Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine* |
| Q40098103 | Disease-induced changes in the plasma binding of basic drugs |
| Q67515762 | Disposition of diethylstilbestrol in the rhesus monkey |
| Q67356884 | Do you need a pharmacokinetic model, and, if so, which one? |
| Q69729736 | Editorial: Babies' blood pressure raised by eye drops |
| Q71795033 | Effect of erythrocyte binding on elimination of harmol by the isolated perfused rat liver |
| Q40104510 | Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs |
| Q41957240 | Effect of rifampicin on metoprolol and antipyrine kinetics |
| Q43670020 | Effect of route of administration and distribution on drug action |
| Q69675577 | Effect of route of administration on drug disposition |
| Q41230560 | Effects of Long-Term Exposure to Environmental Levels of Polychlorinated Biphenyls on Pharmacokinetics of Pentobarbital in Rats |
| Q51806746 | Effects of dose and concentration of rectal methohexitone for induction of anaesthesia in children. |
| Q47214779 | Encapsulated Optically Responsive Cell Systems: Toward Smart Implants in Biomedicine. |
| Q34512168 | Enhanced metabolism of mexiletine after phenytoin administration |
| Q67452905 | Ergot alkaloids: Hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine |
| Q72040522 | Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac |
| Q92887906 | Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems |
| Q67562642 | First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma |
| Q52739041 | First-Pass Metabolism of Ethinyl Estradiol in Dogs and Rats |
| Q34257205 | First-pass elimination. Basic concepts and clinical consequences |
| Q34495150 | Glycerol clearance in alcoholic liver disease |
| Q36063425 | HPLC analysis of in vivo intestinal absorption and oxidative metabolism of salicylic acid in the rat. |
| Q42270983 | Haloperidol pharmacokinetics: A preliminary study in rhesus monkeys using a new radioimmunoassay procedure |
| Q72510088 | Hepatic First-Pass Effect of Thiazinamium Methylsulfate (N-Methylpromethazine Methylsulfate) in Dogs |
| Q44804450 | Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance |
| Q52707737 | Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ pr |
| Q45150779 | Hepatic clearance of local anesthetics in man. |
| Q43001897 | Immediate decrease by hydrocortisone of the plasma half-life of antipyrine |
| Q67595376 | Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol |
| Q88327530 | In Vitro Comparative Study of the Inhibitory Effects of Mangiferin and Its Aglycone Norathyriol towards UDP-Glucuronosyl Transferase (UGT) Isoforms |
| Q39720658 | Individual Differences in the Disposition of Drugs Metabolised in the Body |
| Q46433552 | Influence of cigarette smoking on melatonin levels in man. |
| Q53741350 | Influence of first-pass effect on the systemic availability of propoxyphene. |
| Q39669439 | Influence of food and diet on gastrointestinal drug absorption: a review |
| Q52756203 | Influence of renal failure on the hepatic clearance of bufuralol in man |
| Q71218379 | Influence of route of administration on the pharmacokinetics of methylprednisolone |
| Q71324315 | Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil |
| Q91650386 | Intestine-Liver Axis On-Chip Reveals the Intestinal Protective Role on Hepatic Damage by Emulating Ethanol First-Pass Metabolism |
| Q70576105 | Intraindividual variations of 8-methoxypsoralen plasma levels |
| Q42219259 | Kinetics of ajmaline disposition and pharmacologic response in beagle dogs |
| Q72056212 | Kinetics of citalopram in test animals; drug exposure in safety studies |
| Q34661925 | Kinetics of l-5-hydroxytryptophan in healthy subjects |
| Q43609676 | Lack of effect of withdrawal from cigarette smoking on theophylline pharmacokinetics |
| Q42621842 | Lidocaine decay and hepatic extraction in the pig. |
| Q51619427 | Lidocaine extraction by the in vivo and isolated perfused pig liver. |
| Q34449747 | Lignocaine disposition in blood in epilepsy |
| Q69805064 | Mean time and first-pass metabolism |
| Q72540375 | Metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulfate (Multergan) in man. II. Oral and rectal administration |
| Q43491731 | Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination |
| Q57156824 | Neuropharmacology of attention |
| Q70401467 | Noninvasive measurement of nutrient portal blood shunting: an experimental study with [14C]ursodeoxycholic acid |
| Q70825479 | On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration |
| Q52879375 | On the pharmacokinetics of phenacetin in man |
| Q34450204 | On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction |
| Q34358117 | Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer |
| Q35147092 | Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goats |
| Q52257822 | Organ clearance concepts: new perspectives on old principles. |
| Q34516840 | Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs |
| Q34621171 | Pethidine binding in whole blood: methodology and clinical significance |
| Q52526291 | Phagocytic activity of the rat reticuloendothelial system and the pharmacokinetics of an anticholinesterasic insecticide: carbaryl. |
| Q67557239 | Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes |
| Q52692247 | Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. |
| Q39874224 | Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs |
| Q72486779 | Pharmacokinetic studies in man of the selective beta1-adrenoceptor agonist, prenalterol |
| Q43712645 | Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. |
| Q40323823 | Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol |
| Q71763148 | Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline |
| Q66924040 | Pharmacokinetics of Carbamazepine in Monkeys following Intravenous and Oral Administration |
| Q51661421 | Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man |
| Q44279841 | Pharmacokinetics of diphenhydramine in man |
| Q51860792 | Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. |
| Q42596162 | Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent |
| Q56832437 | Pharmacokinetics of oral and intravenous rifampicin during chronic administration |
| Q67836578 | Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans |
| Q42592600 | Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration |
| Q45264730 | Pharmacokinetics of two per cent rectal methohexitone in children |
| Q40182427 | Physiologic pharmacokinetic models: relevance, experience, and future trends |
| Q33550408 | Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates |
| Q38023217 | Physiological pharmacokinetic modelling |
| Q67021663 | Plasma Isosorbide Dinitrate Concentrations in Human Subjects after Administration of Standard and Sustained-Release Formulations |
| Q67396568 | Plasma concentration of ?-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester |
| Q36647102 | Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data |
| Q52564182 | Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-pharmacokinetic relationships. |
| Q90347887 | Protein Binding and Hepatic Clearance: Re-Examining the Discrimination between Models of Hepatic Clearance with Diazepam in the Isolated Perfused Rat Liver Preparation |
| Q67251872 | Quantitation of hepatic and pulmonary first-pass effect and its implications in pharmacokinetic study. I. Pharmacokinetics of chloroform in man |
| Q34783396 | Quantitation of small intestinal permeability during normal human drug absorption |
| Q34517822 | Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients |
| Q39946968 | Route of Administration and Drug Disposition |
| Q52425644 | Saturable first-pass kinetics of propranolol. |
| Q40316240 | Saturable metabolism and its relationship to toxicity |
| Q48684283 | Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species |
| Q40701397 | Small animal model of weightlessness for pharmacokinetic evaluation |
| Q42126042 | Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique |
| Q57805152 | The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses |
| Q43762566 | The Objective and Timing of Drug Disposition Studies, Appendix IV. Phenylbutazone Formulations: in vitro Dissolution and in vivo Performance |
| Q53853627 | The Possible Role of Cytochrome P-450 in the Liver “First Pass Elimination” of a P-Receptor Blocking Drug |
| Q38649844 | The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio. |
| Q34517399 | The effect of ageing on the hepatic clearance of propranolol |
| Q28332242 | The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse |
| Q34515052 | The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment |
| Q72493618 | The systemic bioavailability of buprenorphine by various routes of administration |
| Q67318979 | Theoretical Relationships between Area under the Curve and Route of Administration of Drugs and Their Precursors for Evaluating Sites and Pathways of Metabolism |
| Q47722116 | Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism |
| Q42739574 | Use of dried blood spots in drug development: pharmacokinetic considerations |
| Q70599280 | Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients |
Search more.